Nanoform 1-12/2020 report and new company near-term target introduced
Nanoform
Company Announcement
Nanoform 1-12/2020 report and new company near-term target introduced
First GMP manufacturing campaign and first dosing in humans successfully completed, positive interim results from first clinical study announced, all near-term business targets set out in IPO achieved, ten new Small Molecule PoC projects started, four more non-GMP lines commissioned, first Biologics PoC project commenced and a new near-term business target introduced: “At least 3 new non-GMP lines in 2021 and 2 new GMP lines in 2022”.
10-12/2020 key financials:
- Revenue was EUR 186 thousand (EUR 49 thousand in 10-12/2019).
- The gross profit and margin came in at EUR 135 thousand and 73%, during 10-12/2019 the gross profit was negative.
Nanoform sets new near-term business target for 2021 and 2022 di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
Nasdaq Nordic: Nasdaq Stockholm Welcomes FluoGuide to the Nasdaq First North Growth Market
Stockholm, February 24, 2020 - Nasdaq (Nasdaq: NDAQ) announces that trading in
FluoGuide A/S shares (short name FLUO) commences today on Nasdaq First North
Growth Market. The company belongs to the Health care sector. FluoGuide is the
12th company to be admitted to trading on Nasdaq s Nordic markets in 2021.
FluoGuide develops surgical solutions that are expected to reduce suffering for
cancer patients and increase the likelihood of cure as well as reducing costs
for the health care system. Intelligent surgical targeting has a potential to
help surgeons reduce costs and time for any kind of surgery. Surgical targeting
Additional Positive Interim Results from Nanoform s Clinical Study
USA - English
Share this article
Share this article
HELSINKI, Feb. 24, 2021 /PRNewswire/ Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study. The fast absorption data implies that small is powerful
® and might offer viable alternatives to complex formulation approaches such as cyclodextrin based technologies.
Nanoform has received the second interim pharmacokinetic (PK) study results related to its Phase 1, single-centre, part crossover, open-label, partially-randomised study designed to evaluate the PK profile of piroxicam following administration of nanoformed oral immediate release (IR) piroxicam tablet and IR reference products in healthy subjects (UNICORN).
Additional Positive Interim Results from Nanoform s Clinical Study prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.